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Pirolimus-Eluting Stents Remain
uperior to Bare-Metal Stents at Two Years
edium-Term Results From the Rapamycin-Eluting Stent
valuated at Rotterdam Cardiology Hospital (RESEARCH) Registry
ndrew T. L. Ong, MBBS, FRACP, Ron T. van Domburg, PHD, Jiro Aoki, MD, Karel Sonnenschein,
edro A. Lemos, MD, PHD, Patrick W. Serruys, MD, PHD, FACC
otterdam, the Netherlands
OBJECTIVES The purpose of this study was to investigate the medium-term (two year) outcome of the
unrestricted utilization of sirolimus-eluting stents (SES) in an all-comer population.
BACKGROUND Despite the implantation of SES in over a million patients to date, limited data exist on
long-term outcomes.
METHODS Sirolimus-eluting stents were used as the default strategy as part of the Rapamycin-Eluting
Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. A total of 508
consecutive patients with de novo lesions exclusively treated with SES were compared with
450 patients who received bare stents in the immediately preceding period (pre-SES group).
RESULTS Patients in the SES group more frequently had multivessel disease, more type C lesions,
received more stents, and had more bifurcation stenting. At two years, the cumulative rate of
major adverse cardiac events (death, myocardial infarction, or target vessel revascularization)
was 15.4% in the SES group and 22.0% in the pre-SES group (hazard ratio [HR] 0.68, 95%
confidence interval [CI] 0.50 to 0.91; p  0.01). The two-year risk of target vessel
revascularization in the SES group and in the pre-SES group was 8.2% and 14.8%,
respectively (HR 0.53, 95% CI 0.36 to 0.79; p  0.002).
CONCLUSIONS In an unrestricted population, the beneficial effects of sirolimus-eluting stent implantation
extend out to two years compared with bare-metal stents, driven by a reduction in
re-intervention rates. These findings should be confirmed by the results of the large
randomized trials. (J Am Coll Cardiol 2006;47:1356–60) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102of Cardiology Foundation
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en the two years since the introduction of drug-eluting
tents worldwide, the take-up has been astounding. Drug-
luting stents now comprise at least 70% of the stent market
n the U.S. and 40% in Europe, and they are increasing with
See page 1361
ime. To date, over 1 million patients have received 1.5
illion sirolimus-eluting stents (SES) worldwide despite a
aucity of long-term follow-up data (1). For simple lesions,
ncouraging two-year results were reported by the first
nvestigations in humans (2,3), as was the recent publication
f the three-year results in the Randomized Study With the
irolimus-Eluting Velocity Balloon-Expandable Stent in
he Treatment of Patients With de Novo Native Coronary
rtery Lesions (RAVEL), the first randomized trial on SES
4). However, fewer than 200 patients with simple lesions
reated with a single 18-mm SES were studied in both trials
ombined.
In porcine models, there have been some concerns re-
arding a late catch-up phenomenon whereby the initial
enefits of SES disappear with time (5). Furthermore,
From the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
upported by the Erasmus Medical Center and by unrestricted institutional grants
rom Cordis, a Johnson & Johnson company.p
Manuscript received April 7, 2005; revised manuscript received May 12, 2005,
ccepted May 17, 2005.nitial attempts at developing an antirestenosis device using
radioactive stent demonstrated that in humans restenosis
nd neointimal hyperplasia were delayed but not prevented
6). Late “unpredictable” events have been anecdotally
eported with drug-eluting stents (7,8).
In the treatment of unselected “all-comer” patients with
omplex disease, our group has previously reported on the
ntermediate results of the Rapamycin-Eluting Stent Eval-
ated at Rotterdam Cardiology Hospital (RESEARCH)
egistry, demonstrating that the use of SES is associated
ith significantly lower incidence of major adverse cardiac
vents (MACE) and target vessel revascularization (TVR)
hen compared with bare-metal stents (BMS) at one year
n patients with de novo coronary artery lesions (9). The
urpose of this report is to investigate whether the beneficial
ffects of SES extend beyond one year and to detail the
ajor adverse cardiac events that have occurred between one
nd two years.
ETHODS
tudy design and patient population. The methodology
f the RESEARCH registry has been reported previously
10). Briefly, RESEARCH is a single-center registry con-
ucted with the main purpose of evaluating the safety and
fficacy of SES implantation for patients treated in daily
ractice. Since April 16, 2002, our institution adopted a
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April 4, 2006:1356–60 Two-Year Results of the RESEARCH Registryolicy of using SES (Cypher; Johnson & Johnson-Cordis
nit, Cordis Europa, Roden, the Netherlands) as the default
trategy for every percutaneous coronary intervention. In the
rst six months of enrollment, 508 patients with de novo
esions were treated exclusively with SES (SES group) and
ompared with a group of 450 consecutive patients treated
ith bare stents for de novo lesions in the preceding six
onths (pre-SES group). The total study population thus
omprised 958 patients divided into two sequential cohorts,
rimarily distinguished by the interventional strategy applied
BMS or SES implantation, respectively) (9). This protocol
as approved by the hospital ethics committee and is in
ccordance with the Declaration of Helsinki. Written in-
ormed consent was obtained from every patient.
rocedures and postintervention medications. All inter-
entions were performed according to current standard
uidelines with the final interventional strategy (including
se of periprocedural glycoprotein IIb/IIIa inhibitors) at the
perator’s discretion. Angiographic success was defined as
esidual stenosis 30% by visual analysis in the presence of
hrombolysis In Myocardial Infarction (TIMI) flow grade 3.
ll patients were advised to maintain lifelong aspirin. At
east one-month clopidogrel treatment (75 mg/day) was
ecommended for patients treated in the pre-SES phase.
or patients treated with SES, clopidogrel was prescribed for at
east three months, unless one of the following was present (in
hich case clopidogrel was maintained for at least 6 months):
ultiple SES implantation (3 stents), total stented length
36 mm, chronic total occlusion, and bifurcations.
efinition of major adverse cardiac events. Major ad-
erse cardiac events were defined as: 1) death; 2) nonfatal
yocardial infarction (MI); or 3) TVR. Myocardial infarc-
ion was diagnosed by a rise in the creatine kinase-MB
raction of more than three times the upper limit of normal
11). Target lesion revascularization (TLR) was defined as a
epeat intervention (surgical or percutaneous) to treat a
uminal stenosis within the stent or in the 5-mm distal or
Abbreviations and Acronyms
BMS  bare-metal stent
CI  confidence interval
HR  hazard ratio
MACE  major adverse cardiac event
MI  myocardial infarction
RAVEL  Randomized Study With the Sirolimus-
Eluting Velocity Balloon-Expandable
Stent in the Treatment of Patients
With de Novo Native Coronary Artery
Lesions
RESEARCH  Rapamycin-Eluting Stent Evaluated at
Rotterdam Cardiology Hospital
SES  sirolimus-eluting stent
TLR  target lesion revascularization
TVR  target vessel revascularizationroximal segments adjacent to the stent. Target vessel
*evascularization was defined as a re-intervention driven by
ny lesion located in the same epicardial vessel.
wo-year follow-up data. For the two-year follow-up,
urvival data for all patients were obtained from municipal
ivil registries. A health questionnaire was sent to all living
atients with specific questions on rehospitalization and
ajor adverse cardiac events. As the principal referral center
ithin the region, repeat procedures (percutaneous and
urgical) are normally performed at our institution and
ecorded prospectively in our database. For patients who
uffered an adverse event at another center, medical records
r discharge summaries from the other institutions were
ystematically reviewed. General practitioners, referring car-
iologists, and patients were contacted as necessary if
urther information was required.
tatistical analysis. Continuous variables are presented as
ean  SD and were compared by means of the Student
npaired t test. Categorical variables are presented as counts
nd percentages and compared by means of the Fisher exact
est. All statistical tests were two tailed. The cumulative
ncidence of adverse events was estimated according to the
aplan-Meier method, and Cox proportional hazards mod-
ls were used to assess risk reduction of adverse events.
atients lost to follow-up were considered at risk until the
ate of last contact, at which point they were censored.
ultivariate analyses were performed to identify independent
redictors of adverse events, using all clinical, angiographic,
nd procedural variables included in Tables 1 and 2.
able 1. Baseline Characteristics of Patients Treated With
onventional Bare-Metal Stents Before the Introduction of SES
Pre-SES Group) and Patients Treated Exclusively With SES
mplantation (SES Group)
Pre-SES
Group
(n  450)
SES
Group
(n  508) p Value
ale, % 72 68 0.4
ge, yrs  SD 61  11 61  11 0.7
iabetes, % 15 18 0.3
on–insulin-dependent, % 11 12 0.7
nsulin-dependent, % 4 6 0.2
ypertension, % 48 41 0.2
ypercholesterolemia, % 55 56 1.0
urrent smoking, % 34 31 0.3
revious myocardial infarction, % 40 30 0.01
revious angioplasty, % 18 19 0.8
revious coronary bypass surgery, % 8 9 0.5
ingle-vessel disease, % 52 46 0.05
ultivessel disease, % 48 54 0.05
linical presentation — — 0.7
table angina, % 48 45 —
nstable angina, % 35 37 —
cute myocardial infarction, % 18 18 —
ardiogenic shock, %* 12 10 0.7Relative to patients with acute myocardial infarction.
SES  sirolimus-eluting stent.
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aseline and procedural characteristics. The baseline and
rocedural characteristics have been previously described
nd are included in Tables 1 and 2 for reference. Briefly,
pproximately half of the patients in both groups were
dmitted with acute coronary syndromes, and diabetes was
resent in 16% of cases. Patients treated with SES had
ignificantly more multivessel disease, more type C lesions,
ore bifurcation stenting, more segments stented, and more
tents used. Also, in the SES group, long stents and stents with
maller diameters were more frequently used. Periprocedural
dministration of glycoprotein IIb/IIIa inhibitors was more
requent in the pre-SES phase (33% vs. 19%; p  0.01). The
ngiographic success rate was similar in both groups.
ne-year follow-up. At one year, the cumulative inci-
ence of death and death or myocardial infarction was
imilar between groups. Patients treated with SES had
ignificantly less death, MI, or TLR at one year than
atients treated in the pre-SES phase (8.8% vs. 12.6%,
espectively; hazard ratio [HR] 0.66, 95% confidence inter-
al [CI] 0.45 to 0.97; p  0.03). Similarly, the one-year
umulative risk of MACE (death, MI, or TVR) was
ignificantly reduced in the SES group (9.7% vs. 14.8% in
he pre-SES group; HR 0.62, 95% CI 0.44 to 0.89; p 
able 2. Angiographic and Procedural Characteristics of
atients Treated With Conventional Bare-Metal Stents Before
he Introduction of SES (Pre-SES Group) and Patients Treated
xclusively With SES Implantation (SES Group)
Pre-SES
Group
(n  450)
SES
Group
(n  508)
p
Value
reated vessel
Left anterior descending, % 59 59 0.8
Left circumflex, % 33 32 0.7
Right coronary artery, % 34 39 0.2
Left main coronary, % 2 3 0.6
Bypass graft, % 2 3 0.2
esion type
A, % 20 22 0.4
B1, % 32 31 0.7
B2, % 50 49 0.8
C, % 30 43 0.01
lycoprotein IIb/IIIa inhibitor, % 33 19 0.01
lopidogrel prescription,
months  SD
2.9  2.0 4.0  2.0 0.01
ifurcation stenting, % 8 16 0.01
umber of stented segments  SD 1.8  0.9 2.0  1.0 0.01
umber of implanted stents  SD 1.9  1.2 2.1  1.4 0.01
ndividual stent length
33 mm, %
10 35 0.01
otal stented length per patient,
mm  SD
30.1  19.6 38.7  28.7 0.01
ominal stent diameter
2.5 mm, %
23 36 0.01
ost-dilation with a balloon
0.5 mm larger, %
19 55 0.01
ngiographic success of all lesions, % 97 97 1.0
ES  sirolimus-eluting stent..008). The difference in outcomes between groups was
C
mainly due to a decrease in the need for TVR in the SES
roup (5.1% vs. 10.9% in the pre-SES group; HR 0.49, 95%
I 0.29 to 0.82; p  0.007).
wo-year follow-up. Follow-up information was obtained
n 97.7% of patients. At two years, there were no significant
ifferences in mortality between the SES and pre-SES groups,
5.8% vs. 6.3%; HR 0.92, 95% CI 0.55 to 1.54; p  0.7)
igure 1. Two-year adverse events in patients treated with bare stents
efore the introduction of sirolimus-eluting stents (SES) (pre-SES group)
nd in patients treated exclusively with SES implantation (SES group). (A)
umulative risk of death. (B) Death or myocardial infarction. (C) Death,
yocardial infarction, or target vessel revascularization.
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April 4, 2006:1356–60 Two-Year Results of the RESEARCH RegistryFig. 1A). The combined end point of death or MI were
lso similar (9.7% vs. 10.9%, respectively; HR 0.89, 95% CI
.60 to 1.33; p  0.6) (Fig. 1B). The two-year incidence of
he combined end point of MACE was lower in the SES
roup than in the pre-SES group (15.4% vs. 22.0%; HR
.68, 95% CI 0.50 to 0.91; p  0.01) (Fig. 1C), driven by
significantly lower incidence of TVR in the SES group
8.2% vs. 14.8%, respectively; HR 0.53, 95% CI 0.36 to
.79; p  0.002) (Fig. 2).
vents from one to two years. Between one and two years,
3 events occurred (Table 3). There were 12 deaths in the
ES group and 9 deaths in the pre-SES group. Two MIs
ccurred in the SES group compared with five in the
re-SES group (p  0.3). Target lesion revascularizations
ere infrequent in both the SES group (n  11) and the
re-SES group (n  14) (p  0.4). Including TLRs, there
ere 13 TVRs in the SES group versus 18 in the pre-SES
roup (p  0.3). Overall MACE occurred in 23 patients in
he SES phase and 30 in the pre-SES phase (p  0.16). In
his RESEARCH registry cohort of 958 patients, no
atient in either group experienced late angiographic stent
hrombosis out to 24 months. Between one and two years,
further five patients in the SES group and six in the
re-SES group required a repeat intervention for a lesion in
different vessel (p  1.0).
igure 2. Two-year cumulative risk of target vessel revascularization in
atients treated with bare stents before the introduction of sirolimus-
luting stents (SES) (pre-SES group) and in patients treated exclusively
ith SES implantation (SES group).
able 3. Number of Events Between One and Two Years
Events Between
1 and 2 Years
Pre-SES
Group
(n  450)
SES
Group
(n  508) p Value
eath, n (%) 9 (2.0) 12 (2.4) 0.8
I, n (%) 5 (1.1) 2 (0.4) 0.3
LR, n (%) 14 (3.1) 11 (2.2) 0.4
VR (includes TLR), n (%) 18 (4.0) 13 (2.6) 0.3
on-TVR, n (%) 5 (1.1) 6 (1.2) 1.0
otal MACE, n (%) 30 (6.7) 23 (4.5) 0.16
ACE  major adverse cardiac event; MI  myocardial infarction; SES e
irolimus-eluting stent; TLR  target lesion revascularization; TVR  target vessel
evascularization.ultivariate predictors of outcomes. Cox regression
nalysis was performed to identify predictors of MACE at
wo years (Table 4). Cardiogenic shock at entry, stenting of
he left main stem, diabetes, history of previous interventions,
nd longer stented lengths were all associated with adverse
ccurrences of MACE (Table 4). A separate Cox regression
nalysis was performed, and predictors of TVR were diabetes,
revious interventions, and longer stented lengths, whereas
cute coronary syndromes at entry was protective. When
djusted for independent predictors, the use of SES conferred
significant protective effect against both TVR (HR 0.45, 95%
I 0.29 to 0.68; p  0.001) and MACE (HR 0.58, 95%
I 0.43 to 0.80; p  0.001) at two-year follow-up.
ISCUSSION
his present paper reports that the beneficial effects of SES
ompared to BMS are maintained out to two years in a
eal-world population. At the end of two years, significantly
ess MACE occurred in the SES group compared to the
re-SES group. In the second year following stent implan-
ation, a trend toward fewer repeat revascularizations oc-
urred in the SES arm with no late catch-up seen.
The reduction in the composite end point of MACE in
he SES group was entirely driven by the component of
VR; the incidences of death and MI were similar in both
roups in the follow-up period. This extends the finding of
large meta-analysis of drug-eluting trials that demon-
trated no reduction in death or MI out to one year with
rug-eluting stents (12).
In this study, although there was a trend toward fewer
able 4. Separate Cox Regression Analyses Performed to
etermine Independent Predictors of MACE and TVR
t Two-Year Follow-Up
HR 95% CI p Value
ACE*
Use of SES 0.58 0.43–0.80 0.001
Total stented length
(per 10-mm increment)
1.12 1.06–1.18 0.001
Previous PCI 1.71 1.20–2.43 0.003
Diabetes mellitus 2.00 1.42–2.80 0.001
Left main stenting 2.23 1.19–4.16 0.01
Cardiogenic shock at entry 4.19 2.04–8.59 0.001
VR†
Use of SES 0.45 0.37–0.68 0.001
Acute coronary syndrome at entry 0.56 0.37–0.83 0.004
Total stented length
(per 10-mm increment)
1.14 1.07–1.22 0.001
Previous PCI 1.73 1.11–2.69 0.016
Diabetes mellitus 2.05 1.33–3.17 0.001
Tested variables: age, gender, multivessel disease, hypertension, current smoking,
ight coronary artery stenting, type C lesion, number of stents, number of segments
reated, use of 33-mm stent, total stent length, previous intervention, diabetes, left
ain stenting, cardiogenic shock, stent type. †Tested variables: current smoking,
ifurcation stenting, number of segments treated, number of stents, acute coronary
yndrome at entry, total stented length, previous intervention, diabetes, stent type.
ariables were included if significant on univariate analysis or if clinically relevant.
CI  confidence interval; HR  hazard ratio; PCI  percutaneous coronary
ntervention; other abbreviations as in Table 3.vents in SES-treated patients (p  0.16) between one and
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Two-Year Results of the RESEARCH Registry April 4, 2006:1356–60wo years, the beneficial effect seen with SES at two years
as driven primarily by the reduction in events in the first
ear. Thus, once the important beneficial effect of neointi-
al suppression had occurred during the period after
tenting, the next step was to detect whether a later rebound
henomenon (as seen in porcine models) occurred in hu-
ans. This first-in-man study with serial angiographic and
ntravascular ultrasound studies was encouraging, demon-
trating in a small population that neointimal suppression
as preserved out to two years. In the RAVEL study,
owever, some nonsignificant late catch-up effect was noted
n the SES arm, with six TLR versus none in the bare group
een between one- and three-year follow-ups; however, the
verall incidence of TLR in the SES arm of remained
ignificantly less than the bare group at three years (4,13).
In our registry, we did not observe any late catch-up
henomenon such as seen with radioactive stents and brachy-
herapy. In fact, during the second year, a trend toward a lower
VR rate was seen in the SES group compared with the
re-SES group (4.0% vs. 2.6%, respectively; p  0.3) (Table
). In addition to the previously described events, approxi-
ately 1% of patients in each group required repeat interven-
ion for progressive disease in a previously nontreated vessel
non-TVR revascularization). Because these lesions do not
enefit from the beneficial local effects of SES, it is imperative
hat intensive risk factor reduction, both physical and pharma-
eutical, are implemented to reduce the potential for progres-
ion of remote lesions (14).
Although it was encouraging that no late angiographic
tent thrombosis events were seen in either group out to two
ears, observation and interpretation of this rare and unex-
ected late complication requires a much larger sample size
nd longer term follow-up (15).
onclusions. The medium-term follow-up of the
ESEARCH registry demonstrates that in the real world SES
educe the incidence of major adverse cardiac events at two
ears of follow-up, primarily by a smaller need for repeat
evascularization of the target vessel compared to bare-metal
tents, already evident during the first year. The reduction in
vents was maintained during the second year with no evidence
f a late-catch up effect. No late angiographic stent thrombosis
as seen out to two years in this cohort of patients studied.
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